After initiating a wind-down more than 18 months ago and exploring liquidation, Galera Therapeutics has found a path forward ...
Strong demand for GLP-1 drugs and next-gen diagnostic testing is pulling investors back into life sciences, even as AI soaks ...
A slow start to 2026 has put first-time biotech financings on course for their worst year since before the pandemic, reducing ...
The high-profile obesity drug developer priced the biotech sector’s biggest offering in years and will use the proceeds to ...
Investor's Business Daily on MSN
Four biotech stocks near buy points as earnings season kicks in
Four biotech stocks in the IBD 50 are in bases as first-quarter earnings rolls in. Travere Therepeutics is below a buy point ...
Seaport Therapeutics, a Boston biotech led by Daphne Zohar, has filed to go public, setting up a Nasdaq debut that could funnel fresh cash into its neuropsychiatric drug pipeline. Spun out of PureTech ...
Equipped with $300 million, Beeline has an oral medicine for the treatment of lupus as well as other experimental drugs ...
From the Capital of France to the Capital of New York — a cutting-edge biotech firm that uses AI to research cancer ...
The Fremont company sold extra shares at the top of its proposed range, and the stock jumped more than 30% in initial trading ...
For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...
In this article, we will look at the 8 Most Undervalued Biotech Stocks to Buy Right Now. On April 13, Tom Lee, Fundstrat’s ...
Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results